Dermatitis News

The National Eczema Association has dedicated October to raising eczema awareness, with 2021 focused on the varied disease experiences among those living with and caring for this condition.

Tralokinumab significantly improved atopic dermatitis in adolescents, according to phase 3 trial results presented at the 2021 Fall Clinical Dermatology Conference.

Children with atopic dermatitis, but not those with psoriasis, were likely to be absent from school at least 15 days a year due to their condition, according to a study.

Delgocitinib ointment was associated with improved efficacy over placebo in pediatric patients with moderate atopic dermatitis through 56 weeks of follow-up, according to a study.

Significant improvements were seen in atopic dermatitis symptoms in patients treated with an anti-OX40 monoclonal antibody, as well as continued improvement after discontinuation, according to phase 2 trial results.

An extension study found atopic dermatitis patients continuously treated with tralokinumab had long-term improvement in severity and those with interrupted treatment matched improvement after 12 weeks.

Remibrutinib provided significant improvement in chronic spontaneous urticaria in a phase 2b dose affirming trial presented at the EADV virtual congress.

Weekly dupilumab showed long-term safety and efficacy in atopic dermatitis patients in an open-label extension study presented at the EADV Congress virtual meeting.

In this video, April W. Armstrong, MD, MPH, professor of dermatology and associate dean at Keck School of Medicine at USC, discusses what it means to patients to be diagnosed with psoriasis.

Patients with mild to severe atopic dermatitis may benefit from long-term upadacitinib and topical corticosteroid treatment without any new safety risks, according to a study published in The Journal of Allergy and Clinical Immunology.